A ruthenium complexes of monastrol and its pyrimidine analogues: Synthesis and biological properties

References

• Li, F.; Collins, J. G.; Keene, F. R. Ruthenium Complexes as Antimicrobial Agents. Chem. Soc. Rev. 2015, 44, 2529–2542. DOI:10.1039/C4CS00343H.
   PubMed Web of Science ®Google Scholar
• Dragutan, I.; Dragutan, V.; Demonceau, A. Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes. Molecules 2015, 20, 17244–17274. DOI:10.3390/molecules200917244.
   PubMed Web of Science ®Google Scholar
• Zeng, L.; Gupta, P.; Chen, Y.; Wang, E.; Ji, L.; Chao, H.; Chen, Z. S. The Development of Anticancer Ruthenium(ii) Complexes: From Single Molecule Compounds to Nanomaterials. Chem. Soc. Rev. 2017, 46, 5771–5804. DOI:10.1039/C7CS00195A.
   PubMed Web of Science ®Google Scholar
• Süss-Fink, G. Arene Ruthenium Complexes as Anticancer Agents. Dalton Trans. 2010, 39, 1673–1688. DOI:10.1039/B916860P.
   PubMed Web of Science ®Google Scholar
• Furrer, J.; Süss-Fink, G. Thiolato-Bridged Dinuclear Arene Ruthenium Complexes and Their Potential as Anticancer Drugs. Coord. Chem. Rev. 2016, 309, 36–50. DOI:10.1016/j.ccr.2015.10.007.
   Web of Science ®Google Scholar
• Mestroni, G.; Alessio, E.; Calligaris, M.; Attia, W. M.; Quadrifoglio, F.; Cauci, S.; Sava, G.; Zorzet, S.; Pacor, S. In Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy, Alessio, E.; Clarke, M. J. Eds., Springer-Verlag: Berlin, New York, 1989; pp. 71–87.
   Google Scholar
• Dale, L. D.; Tocher, J. H.; Dyson, T. M.; Edwards, D. I.; Tocher, D. A. Studies on DNA Damage and Induction of SOS Repair by Novel Multifunctional Bioreducible Compounds. II. A Metronidazole Adduct of a Ruthenium-Arene Compound. Anticancer Drug Des. 1992, 7, 3–14. DOI:10.1016/S0020-1693(00)87653-7.
   PubMedGoogle Scholar
• Dyson, P. J. Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-Clinical Development. Chimia 2007, 61, 698–703. DOI:10.2533/chimia.2007.698.
   Web of Science ®Google Scholar
• Dougan, S. J.; Sadler, P. J. The Design of Organometallic Ruthenium Arene Anticancer Agent. Chimia 2007, 61, 704–715. DOI:10.2533/chimia.2007.704.
   Web of Science ®Google Scholar
• Allardyce, C. S.; Dyson, P. J.; Ellis, D. J.; Heath, S. L. [Ru(η6-p-Cymene)Cl2(Pta)] (Pta = 1,3,5-Triaza-7-Phosphatricyclo- [3.3.1.1]Decane): A Water Soluble Compound That Exhibits pH Dependent DNA Binding Providing Selectivity for Diseased Cells. Chem. Commun. 2001, 1396–1397. DOI:10.1039/b104021a.
   Web of Science ®Google Scholar
• Morris, R. E.; Aird, R. E.; del Socorro Murdoch, P.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; et al. Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes. J. Med. Chem. 2001, 44, 3616–3621. DOI:10.1021/jm010051m.
   PubMed Web of Science ®Google Scholar
• Bergamo, A.; Sava, S. Ruthenium Complexes Can Target Determinants of Tumour Malignancy. Dalton Trans. 2007, 13, 1267–1272. DOI:10.1039/b617769g.
   Google Scholar
• Sava, G.; Bergamo, A.; Zorzet, S.; Gava, B.; Casarsa, C.; Cocchietto, M.; Furlani, A.; Scarcia, V.; Serli, B.; Iengo, E.; et al. Influence of Chemical Stability on the Activity of the Antimetastasis Ruthenium Compound NAMI-A. Eur. J. Cancer 2002, 38, 427–435. DOI:10.1016/S0959-8049(01)00389-6.
   PubMed Web of Science ®Google Scholar
• Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From Bench to Bedside–Preclinical and Early Clinical Development of the Anticancer Agent Indazolium Trans-[Tetrachlorobis(1H-Indazole)Ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 2006, 100, 891–904. 02.013. DOI:10.1016/j.jinorgbio.2006.
   PubMed Web of Science ®Google Scholar
• Lentz, F.; Drescher, A.; Lindauer, A.; Henke, M.; Hilger, R. A.; Hartinger, C. G.; Scheulen, M. E.; Dittrich, C.; Keppler, B. K.; Jaehde, U. Pharmacokinetics of a Novel Anticancer Ruthenium Complex (KP1019, FFC14A) in a Phase I Dose-Escalation Study. Anticancer Drugs 2009, 20, 97–103. DOI:10.1097/CAD.0b013e328322fbc5.
   PubMed Web of Science ®Google Scholar
• Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, a New Redox-Active Anticancer Agent–Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. C&B 2008, 5, 2140–2155. DOI:10.1002/cbdv.200890195.
   Google Scholar
• Bregman, H.; Carroll, P. J.; Meggers, E. Rapid Access to Unexplored Chemical Space by Ligand Scanning around a Ruthenium Center: Discovery of Potent and Selective Protein Kinase Inhibitors. J. Am. Chem. Soc. 2006, 128, 877–884. DOI:10.1021/ja.055523r.
   PubMed Web of Science ®Google Scholar
• Al-Masoudi, W. A.; Al-Masoudi, N. A.; Weibert, B.; Winter, R. Synthesis, X-Ray Structure, In Vitro HIV and Kinesin Eg5 Inhibition Activities of New Arene Ruthenium Complexes of Pyrimidine Analogs. J. Coord. Chem. 2017, 70, 2061–2073. DOI:10.1080/00958972.2017.1334259.
   Web of Science ®Google Scholar
• Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen. Science 1999, 286, 971–974. DOI:10.1021/acschembio.6b00203.
   PubMed Web of Science ®Google Scholar
• Cini, R.; Tamasi, G.; Defazio, S.; Corsini, M.; Zanello, P.; Messori, L.; Marcon, G.; Piccioli, F.; Orioli, P. Study of Ruthenium(II) Complexes with Anticancer Drugs as Ligands. Design of Metal-Based Phototherapeutic Agents. Inorg. Chem. 2003, 42, 8038–8052. DOI:10.1021/ic0349095.
   PubMed Web of Science ®Google Scholar
• Marchenko, A. A.; Huffman, J. C.; Valerga, P.; Tenorio, M. J.; Puerta, M. C.; Caulton, K. G. Effect of Lewis Acidity on the Synthesis of RuHCl(CO)(Phosphine)2: Subtle Influence of Steric and Electronic Effects among PiPr3, PiPr2(3,5-(CF3)2C6H3), and PiPr2Me. Inorg. Chem. 2001, 40, 6444–6450. DOI:10.1021/ic000500t.
   PubMed Web of Science ®Google Scholar
• Al-Masoudi, N. A.; Saleh, B. A.; Karim, N. A.; Issa, A. Y.; Pannecouque, C. Synthesis and anti‐HIV Activity of New 2‐Thiolumazine and 2‐Thiouracil Metal Complexes. Heteroatom Chem. 2011, 22, 44–50. DOI:10.1002/hc.20654.
   Web of Science ®Google Scholar
• Raper, E. S. Complexes of Heterocyclic Thione Donors. Coord. Chem. Rev. 1985, 61, 115–185. DOI:10.1016/0010-8545(85)80004-7.
   Web of Science ®Google Scholar
• Prasanna, P.; Sriivasa, S.; Rajagopal, G.; Athappan, P. R. Synthesis, Spectral and Electrochemical Studies of Ruthenium(II)/(III) Complexes of Alicyclic β-Ketamines. Indian J. Chem. 2001, 40A, 426–429.
   Google Scholar
• Ejidike, I. P.; Ajibade, P. A. Synthesis, Characterization, Anticancer, and Antioxidant Studies of Ru(III) Complexes of Monobasic Tridentate Schiff Bases. Bioinorg. Chem. Appl. 2016, 2016, 1–11. DOI:10.1155/2016/9672451.
   Google Scholar
• Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds; Wiley: New York, 1970.
   Google Scholar
• Alessio, E.; Mestroni, G.; Nardin, G.; Attia, W. M.; Calligaris, M.; Sava, G.; Zorzet, S. Cis- and Trans-Dihalotetrakis(Dimethyl Sulfoxide)Ruthenium(II) Complexes (RuX2(DMSO)4; X = Cl, Br): Synthesis, Structure, and Antitumor Activity. Inorg. Chem. 1988, 27, 4099–4106. DOI:10.1021/ic00296a006.
   Web of Science ®Google Scholar
• Sava, G.; Giraldi, T.; Mestroni, G.; Zassinovich, G. Antitumor Effects of Rhodium(I), Iridium(I) and Ruthenium(II) Complexes in Comparison with Cis-Dichlorodiammino Platinum(II) in Mice Bearing Lewis Lung Carcinoma. Chem. Biol. Interact. 1983, 45, 1–6. DOI:10.1016/0009-2797(83)90037-6.
   PubMed Web of Science ®Google Scholar
• Chan, P. K. L.; James, B. R.; Frost, D. C.; Chan, P. K. H.; Hu, H.-L.; Skov, K. A. Effects of Halide (X) and Sulfoxide (R2SO) Replacement within the Ruthenium(II) Nitroimidazole Complexes, RuX2(R2SO)m, (Nitroimidazole)n, m = 1–3, n = 1 or 2: their Characterization, Solution Chemistry, Radiosensitizing Activity, and Related Properties. Can. J. Chem. 1989, 67, 508–516. DOI:10.1139/v89-078b.
   Web of Science ®Google Scholar
• Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M. In Metal Complexes in Cancer Chemotherapy, Keppler, B. K., Ed.; VCH Verlag, Weinheim, 1994; p. 159.
   Google Scholar
• Garza-Ortiz, A.; Maheswari, P. U.; Siegler, M.; Spek, A. L.; Reedijk, J. A New Family of Ru(II) Complexes with a Tridentate Pyridine Schiff-Base Ligand and Bidentate co-Ligands: synthesis, Characterization, Structure and in Vitro Cytotoxicity Studies. New J. Chem. 2013, 37, 3450–3460. DOI:10.1039/c3nj00415e.
   Web of Science ®Google Scholar
• Gaur, R.; Mishra, L. Synthesis and Characterization of Ru(II)-DMSO-Cl-Chalcone Complexes: DNA Binding, Nuclease, and Topoisomerase II Inhibitory Activity. Inorg. Chem. 2012, 51, 3059–3070. DOI:10.1021/ic202440r.
   PubMed Web of Science ®Google Scholar
• Martínez, A.; Carreon, T.; Iniguez, E.; Anzellotti, A.; Sánchez, A.; Tyan, M.; Sattler, A.; Herrera, L.; Maldonado, R. A.; Sánchez-Delgado, R. A. Searching for New Chemotherapies for Tropical Diseases: Ruthenium–Clotrimazole Complexes Display High In Vitro Activity against Leishmania major and Trypanosoma cruzi and Low Toxicity toward Normal Mammalian Cells. J. Med. Chem. 2012, 55, 3867–3877. DOI:10.1021/jm300070h.
   PubMed Web of Science ®Google Scholar
• Ferrer, I.; Fontrodona, Z.; Rodríguez, M.; Romero, I. Ru(II)-Dmso Complexes Containing Azole-Based Ligands: synthesis, Linkage Isomerism and Catalytic Behavior. Dalton Trans. 2016, 45, 3163–3174. DOI:10.1039/C5DT04376J.
   PubMed Web of Science ®Google Scholar
• Henn, M.; Alessio, E.; Mestroni, G.; Calligaris, M.; Attia, W. M. Ruthenium(II)-Dimethyl Sulfoxide Complexes with Nitrogen Ligands: synthesis, Characterization and Solution Chemistry. The Crystal Structures of Cis,fac-RuCl2(DMSO)3(NH3) and Trans,Cis,cis-RuCl2(DMSO)2(NH3)2·H2O. Inorg. Chim. Acta. 1991, 187, 39–50. DOI:10.1016/S0020-1693(00)82975-8.
   Web of Science ®Google Scholar
• Kappe, C. V.; Shishkin, O. V.; Uray, G.; Verdino, P. X-Ray Structure, Conformational Analysis, Enantioseparation, and Determination of Absolute Configuration of the Mitotic Kinesin Eg5 Inhibitor Monastrol. Tetrahedron 2000, 56, 1859–1862. DOI:10.1016/S0040-4020(00)00116-2.
   Web of Science ®Google Scholar
• Ferraro, R. Low Frequency Vibration of Inorganic and Coordination Compounds; Plenum Press: New York, 1971.
   Google Scholar
• Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolium-Based Colorimetric Assay for the Detection of HIV Replication Inhibitors: revisited 20 Years Later. Nat. Protoc. 2008, 3, 427–434. DOI:10.1038/nprot.2007.517.
   PubMed Web of Science ®Google Scholar
• Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; et al. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231–2241. DOI:10.1021/jm00111a045.
   PubMed Web of Science ®Google Scholar
• Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3'-Azido-3'-Deoxythymidine (BW A509U): an Antiviral Agent That Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in Vitro. Proc. Natl. Acad. Sci. USA 1985, 82, 7096–7100. DOI:10.1073/pnas.82.20.7096.
   PubMed Web of Science ®Google Scholar
• Zhou, Z.; Fu, X. D. Regulation of Splicing by SR Proteins and SR Protein-Specific Kinases. Chromosoma 2013, 122, 191–207. DOI:10.1007/s00412-013-0407-z.
   PubMed Web of Science ®Google Scholar
• Schmitt, C.; Miralinaghi, P.; Mariano, M.; Hartmann, R. W.; Engel, M. Hydroxybenzo-Thiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4. ACS Med. Chem. Lett. 2014, 5, 963–967. DOI:10.1021/ml500059y.
   PubMed Web of Science ®Google Scholar